Changes in Hong Kong stocks | Xianjian Technology (01302) rose more than 3% LantValTM aortic valve replacement system to enter a special review process for innovative medical devices

The Zhitong Finance App learned that Xianjian Technology (01302) rose more than 3%. As of press release, it had risen 1.48% to HK$1.37, with a turnover of HK$8.740,600.

According to the news, Xianjian Technology issued an announcement. On September 9, 2026, the company received an official written notice from the China Drug Administration (China Drug Administration) confirming that the LantValTM aortic valve replacement system jointly developed by the Company's subsidiary Shenzhen Jianxin Medical Technology Co., Ltd. (Jianxin Medical) and Fuwai Hospital of the Chinese Academy of Medical Sciences of the National Cardiovascular Center has entered the special review procedure for innovative medical devices by the State Drug Administration.

According to reports, this product is suitable for surgical treatment of patients with aortic stenosis or stenosis with incomplete closure. It is the world's first fully preinstalled dry valve design (no stitching) aortic valve replacement product. It is the company's 18th product to enter the National Drug Administration's procedure. The Group owns independent intellectual property rights for this product. Currently, pre-marketing registration clinical studies for this product are about to commence. As subsequent clinical trials progress steadily, there will be more high-quality evidence-based medical evidence to further confirm the safety and efficacy of this product.